Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Sarcoma 1Penile Neoplasms 1PD-L1 Positive Mutation Tumor 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1Hemangiosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pegaspargase 14Etoposide 11Dexamethasone 11Gemcitabine 10spartalizumab 6Oxaliplatin 4sintilimab 3Radiotherapy 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methotrexate 3Asparaginase 3tislelizumab 2camrelizumab 2Lenalidomide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2Busulfan 2Azacitidine 2toripalimab 1tofacitinib 1ruxolitinib 1romidepsin 1pembrolizumab 1fludarabine phosphate 1avelumab 1apatinib 1Thalidomide 1Sensitivity and Specificity 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Extranodal NK-T-Cell × avelumab × Clear all
NCT03439501 2021-09-24

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Samsung Medical Center

Phase 2 Unknown
21 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡